Table 1.
PPH | PAMAM | PPI | PCSi | P-Lys | Experiment | Ref. |
---|---|---|---|---|---|---|
-NEt2H)96 | -NH3)64 | -NMe3)24 | Clinical tests | [35] | ||
-NEt2H)96 | -NH3)64 | Transfection | [37] | |||
-NEt2H)48/ -NEt2H)96 |
-NH3)32/ -NH3)64 |
-NMe3)8 | Protection SiRNA 1 | [38] | ||
-NEt2H)48/ -NEt2H)96 |
-NH3)32/ -NH3)64 |
-NMe3)8 | Carrier of Si RNA | [39] | ||
-NEt2H)96 |
-NH3)64/ -NH3)128 |
-NH3)16 | Peptide aggregation scavenger | [40] | ||
-NEt2H)96 | -NH3)64/ -NH3)128 |
-NH3)16 | Interaction with heparin | [41] | ||
-NEt2H)48/ -NEt2H)96 |
-NH3)32/ -NH3)64 |
Decrease ROS 2 levels | [44] | |||
(PO3HNa)2]12 | (PO3HNa)2]8 | Against RA 3 | [53] | |||
(PO3HNa)2]12 4 | (PO3HNa)2]8 | (PO3HNa)2]8 | (PO3HNa)2]8 | (PO3HNa)2]8 | Activation of monocytes | [54] |
1 Small interfering RNA. 2 Reactive Oxygen Species. 3 Rheumatoid Arthritis. 4 Same efficiency with PPH (PO3HNa)2]8 [50].